Accupril Quinapril HCl Tablets Recalled for Elevated Nitrosamine Impurity
Pfizer is recalling Accupril (Quinapril HCl) 20 mg tablets nationwide and in Puerto Rico due to N-nitrosoquinapril levels exceeding acceptable limits. Affected lots include DX8682 and DG1188.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a prescription medication contaminated with N-nitrosoquinapril, a known carcinogenic impurity. No illnesses or injuries have been reported, which per the rubric places this in the 'high-risk products where injury has not yet been reported' category.
Plain-English summary
Pfizer is recalling Accupril (Quinapril HCl Tablets) 20 mg, 90-tablet bottles due to Current Good Manufacturing Practice (CGMP) deviations. The recalled product contains N-nitrosoquinapril above acceptable limits.
N-nitrosoquinapril is a potential carcinogenic impurity. The presence of this substance above acceptable levels represents a manufacturing deviation from required quality standards.
The recall affects 10,304 bottles distributed nationwide and in Puerto Rico. Affected lot numbers are DX8682 (expiring March 31, 2023) and DG1188 (expiring March 31, 2022).
Patients currently taking Accupril from the affected lots should contact their healthcare provider or pharmacist for guidance. Do not discontinue medication without consulting a healthcare professional, as the underlying condition being treated may require continued therapy.
The recalled product
- Product
- Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
- Manufacturer
- Pfizer Inc.
- Affected units
- 10,304
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: DX8682 Exp. MAR 31 2023
- DG1188 Exp. MAR 31 2022
Distribution
Part of a larger recall action
This product is one of 3 recalled by Pfizer Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Pfizer Inc.
See all →- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighEpinephrine injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighBicillin L-A 2.4 million unit vials recalled after particulates found
FDA (Drugs) · 2025-08-06
- HighBicillin L-A penicillin vials recalled after particulates found during visual inspection
FDA (Drugs) · 2025-08-06
- ModerateDobutamine Injection Recall Due to Discoloration and Cracked Vials
FDA (Drugs) · 2025-07-02
Same hazard · nitrosamine
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over a nitrosamine impurity
FDA (Drugs) · 2026-02-11
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12